CDK5 and Parkinson disease: These findings suggest a new hypothesis that c-Abl signaling might be implicated in striatal function and raise the possibility that a c-Abl inhibitor might inhibit Cdk5/DARPP-32-pThr75 signaling, thereby serving as a tool in treating PD symptoms.